Skip to content

Trial to Test Effectiveness of Depression Intervention for Mistreated Older Adults

EM/PROTECT-Hybrid: Improving Depression in Elder Mistreatment Victims

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04258579
Enrollment
40
Registered
2020-02-06
Start date
2020-07-15
Completion date
2022-08-11
Last updated
2023-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety, Depression, Depression in Old Age, Elder Abuse

Keywords

Mental Health

Brief summary

The investigators developed EM/PROTECT, a behavioral intervention for depressed EM (elderly mistreatment) victims, to work in synergy with EM mistreatment resolution services that provide safety planning, support services, and links to legal services. PROTECT is built on a model which postulates that chronic stress promotes dysfunction of the cognitive control (CCN) and reward networks, impairing the victims' ability to flexibly respond to the environment and limits their reward activities. PROTECT therapists work with victims to develop action plans to reduce stress, and to increase rewarding experiences. EM/PROTECT has been designed in an iterative process with community EM providers of the New York City (NYC) Department for the Aging (DFTA) to use agencies' routine PHQ-9 depression screening and referral for service. In the current study, the investigators will compare the effectiveness of EM/PROTECT with EM enriched with staff training in linking EM victims to community mental health services (EM/MH). The investigators intend to enroll 50 subjects that will participate in the study for approximately 12 weeks.

Interventions

BEHAVIORALPROTECT with Technology Augmentation

PROTECT is a therapeutic intervention focused on treating victims of elder abuse who are experiencing depression. PROTECT therapy will be delivered through video. Participants will be provided with a mobile device (iPhone), and a wearable device (smart watch) that will track sleep, mood, steps, and heart rate.

Sponsors

National Institute of Mental Health (NIMH)
CollaboratorNIH
Weill Medical College of Cornell University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

The investigators will be comparing data collected from this project to previously collected data from the first phase of this project, in which PROTECT was delivered only in-person.

Eligibility

Sex/Gender
ALL
Age
55 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* 55 years of age or older * Capacity to consent (per Elder Mistreatment staff) * Significant depression (per Elder Mistreatment staff) as indicated by a score of 10 or above on the Patient Health Questionnaire-9 (PHQ-9), a widely used screening tool routinely administered in Elder Mistreatment (EM) agency settings (the PHQ-9 has a sensitivity of 88% and a specificity of 88% for major depression) * Need for EM services

Exclusion criteria

* Active suicidal ideation (Montgomery Asberg Depression Rating Scale item 10\>4) * Inability to speak English or Spanish * Axis 1 Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) diagnoses other than unipolar depression or generalized anxiety disorder (by Structured Clinical Interview for DSM-5) * Severe or life-threatening medical illness * EM emergency and or referral out of EM agency (per EM staff)

Design outcomes

Primary

MeasureTime frameDescription
Change in Clinically Significant Depressive Symptoms as Measured by the MADRS6 weeks, 9 weeks, 12 weeksIn all conditions, the change in clinically significant depressive symptoms as measured on the Montgomery Asberg Depression Rating Scale (MADRS). Scores are categorized as following: 0 to 6 - Normal /symptom absent. 7 to 19 - Mild depression. 20 to 34 - Moderate depression. \>34 - Severe depression. The scores presented for each time point are absolute values.
Change in Assessment of Quality of Life, as Measured by the WHO-QOL6 weeks, 9 weeks, 12 weeksIn all conditions, changes in assessment of quality of life measured by the World Health Organization Quality of Life (WHO-QOL) scale. World Health Organization-Quality Of Life scale. The overall scores range between 26-130. In all domains, higher scores indicate better health. Domain 1 measures physical health (scores range from 7-35). Domain 2 measures psychological health (scores range from 6-30). Domain 3 measures social health (scores range from 3-15). Domain 4 measures environmental health (scores range from 8-40). The scores presented for each time point are absolute values.
Change in Assessment of Stress, as Measured by the PSSBaseline, 6 weeksIn all conditions, changes in assessment of stress measured by the Perceived Stress Scale (PSS) scale. Scores range from 0-40. Scores ranging from 0-13 are considered low stress, scores ranging from 14-26 are considered moderate stress, and scores ranging from 27-40 are considered high perceived stress.

Secondary

MeasureTime frameDescription
Change in Assessment of Exposure to Meaningful Activities, as Measured by the BADSBaseline, 6 weeksIn all conditions, changes in assessment of meaningful activities measured by the Behavioral Activation for Depression Scale (BADS). Scores are divided across 4 domains: Activation subscale scores range from 0-42, Avoidance/Rumination subscale scores range from 0-48, Work/School Impairment subscale scores range from 0-30, Social Impairment subscale scores range from 0-30. For all subscales, high scores are consistent with the subscale title (e.g., high scores on Activation subscale = more activation).

Countries

United States

Participant flow

Participants by arm

ArmCount
Video PROTECT
Participants will receive PROTECT therapy once a week for 9 weeks. PROTECT with Technology Augmentation: PROTECT is a therapeutic intervention focused on treating victims of elder abuse who are experiencing depression. PROTECT therapy will be delivered through video. Participants will be provided with a mobile device (iPhone), and a wearable device (smart watch) that will track sleep, mood, steps, and heart rate.
40
Total40

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyAdverse Event1
Overall StudyLost to Follow-up3
Overall StudyProtocol Violation2
Overall StudyWithdrawal by Subject7

Baseline characteristics

CharacteristicVideo PROTECT
Age, Continuous70.50 years
STANDARD_DEVIATION 6.97
Assessment of Meaningful Activities, as Measured by the BADS
Domain 1
19.89 units on a scale
STANDARD_DEVIATION 8.29
Assessment of Meaningful Activities, as Measured by the BADS
Domain 2
22.46 units on a scale
STANDARD_DEVIATION 8.57
Assessment of Meaningful Activities, as Measured by the BADS
Domain 3
16.00 units on a scale
STANDARD_DEVIATION 7.14
Assessment of Meaningful Activities, as Measured by the BADS
Domain 4
17.79 units on a scale
STANDARD_DEVIATION 7.66
Assessment of Quality of Life, as Measured by the WHO-QOL
Domain 1
21.38 units on a scale
STANDARD_DEVIATION 6.34
Assessment of Quality of Life, as Measured by the WHO-QOL
Domain 2
18.08 units on a scale
STANDARD_DEVIATION 5.04
Assessment of Quality of Life, as Measured by the WHO-QOL
Domain 3
8.45 units on a scale
STANDARD_DEVIATION 3.03
Assessment of Quality of Life, as Measured by the WHO-QOL
Domain 4
25.30 units on a scale
STANDARD_DEVIATION 6.26
Assessment of Stress, as Measured by the PSS22.45 units on a scale
STANDARD_DEVIATION 7.74
Clinically Significant Depressive Symptoms, as Measured by the MADRS23.00 units on a scale
STANDARD_DEVIATION 8.22
Ethnicity (NIH/OMB)
Hispanic or Latino
4 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
36 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
1 Participants
Race (NIH/OMB)
Black or African American
22 Participants
Race (NIH/OMB)
More than one race
2 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants
Race (NIH/OMB)
White
14 Participants
Sex: Female, Male
Female
34 Participants
Sex: Female, Male
Male
6 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 40
other
Total, other adverse events
4 / 40
serious
Total, serious adverse events
2 / 40

Outcome results

Primary

Change in Assessment of Quality of Life, as Measured by the WHO-QOL

In all conditions, changes in assessment of quality of life measured by the World Health Organization Quality of Life (WHO-QOL) scale. World Health Organization-Quality Of Life scale. The overall scores range between 26-130. In all domains, higher scores indicate better health. Domain 1 measures physical health (scores range from 7-35). Domain 2 measures psychological health (scores range from 6-30). Domain 3 measures social health (scores range from 3-15). Domain 4 measures environmental health (scores range from 8-40). The scores presented for each time point are absolute values.

Time frame: 6 weeks, 9 weeks, 12 weeks

Population: The overall number of participants analyzed was 30 at week 6, 30 at week 9, and 26 at week 12. The decline in participants analyzed at each time point is due to participant withdrawal by the study team or by their request.

ArmMeasureGroupValue (MEAN)Dispersion
Video PROTECTChange in Assessment of Quality of Life, as Measured by the WHO-QOLWeek 6 Outcomes- Domain 122.10 units on a scaleStandard Deviation 6.39
Video PROTECTChange in Assessment of Quality of Life, as Measured by the WHO-QOLWeek 6 Outcomes- Domain 219.90 units on a scaleStandard Deviation 4.99
Video PROTECTChange in Assessment of Quality of Life, as Measured by the WHO-QOLWeek 6 Outcomes- Domain 38.93 units on a scaleStandard Deviation 3.36
Video PROTECTChange in Assessment of Quality of Life, as Measured by the WHO-QOLWeek 6 Outcomes- Domain 426.63 units on a scaleStandard Deviation 6.18
Video PROTECTChange in Assessment of Quality of Life, as Measured by the WHO-QOLWeek 9 Outcomes- Domain 122.53 units on a scaleStandard Deviation 7.24
Video PROTECTChange in Assessment of Quality of Life, as Measured by the WHO-QOLWeek 9 Outcomes- Domain 221.00 units on a scaleStandard Deviation 5.71
Video PROTECTChange in Assessment of Quality of Life, as Measured by the WHO-QOLWeek 9 Outcomes- Domain 38.69 units on a scaleStandard Deviation 3.49
Video PROTECTChange in Assessment of Quality of Life, as Measured by the WHO-QOLWeek 9 Outcomes- Domain 427.38 units on a scaleStandard Deviation 6.18
Video PROTECTChange in Assessment of Quality of Life, as Measured by the WHO-QOLWeek 12 Outcomes- Domain 122.62 units on a scaleStandard Deviation 6.04
Video PROTECTChange in Assessment of Quality of Life, as Measured by the WHO-QOLWeek 12 Outcomes- Domain 221.58 units on a scaleStandard Deviation 4.31
Video PROTECTChange in Assessment of Quality of Life, as Measured by the WHO-QOLWeek 12 Outcomes- Domain 39.19 units on a scaleStandard Deviation 3.14
Video PROTECTChange in Assessment of Quality of Life, as Measured by the WHO-QOLWeek 12 Outcomes- Domain 427.81 units on a scaleStandard Deviation 5.64
95% CI: [19.84, 23.32]
95% CI: [7.92, 10.46]
95% CI: [19.7, 24.5]
95% CI: [18, 21.8]
95% CI: [7.68, 10.18]
95% CI: [24.32, 28.94]
95% CI: [19.87, 25.23]
95% CI: [18.87, 23.13]
95% CI: [7.39, 9.99]
95% CI: [25.07, 29.69]
95% CI: [20.18, 25.06]
95% CI: [25.53, 30.09]
Primary

Change in Assessment of Stress, as Measured by the PSS

In all conditions, changes in assessment of stress measured by the Perceived Stress Scale (PSS) scale. Scores range from 0-40. Scores ranging from 0-13 are considered low stress, scores ranging from 14-26 are considered moderate stress, and scores ranging from 27-40 are considered high perceived stress.

Time frame: Baseline, 6 weeks

Population: Due to participant withdrawal and loss to follow-up, the total number of participants at Week 6 was 30.

ArmMeasureGroupValue (MEAN)Dispersion
Video PROTECTChange in Assessment of Stress, as Measured by the PSSBaseline22.45 units on a scaleStandard Deviation 7.74
Video PROTECTChange in Assessment of Stress, as Measured by the PSSWeek 620.53 units on a scaleStandard Deviation 7.71
95% CI: [19.56, 25.34]
95% CI: [17.65, 23.41]
Primary

Change in Clinically Significant Depressive Symptoms as Measured by the MADRS

In all conditions, the change in clinically significant depressive symptoms as measured on the Montgomery Asberg Depression Rating Scale (MADRS). Scores are categorized as following: 0 to 6 - Normal /symptom absent. 7 to 19 - Mild depression. 20 to 34 - Moderate depression. \>34 - Severe depression. The scores presented for each time point are absolute values.

Time frame: 6 weeks, 9 weeks, 12 weeks

Population: The overall number of participants analyzed was 40 at baseline, 30 at week 6, 30 at week 9, and 26 at week 12. The decline in participants analyzed at each time point is due to participant withdrawal by the study team or by their request.

ArmMeasureGroupValue (MEAN)Dispersion
Video PROTECTChange in Clinically Significant Depressive Symptoms as Measured by the MADRSWeek 6 Outcomes19.13 units on a scaleStandard Deviation 9.47
Video PROTECTChange in Clinically Significant Depressive Symptoms as Measured by the MADRSWeek 9 Outcomes16.87 units on a scaleStandard Deviation 11.69
Video PROTECTChange in Clinically Significant Depressive Symptoms as Measured by the MADRSWeek 12 Outcomes15.00 units on a scaleStandard Deviation 9.32
95% CI: [15.59, 22.67]
95% CI: [12.5, 21.24]
95% CI: [11.24, 18.76]
Secondary

Change in Assessment of Exposure to Meaningful Activities, as Measured by the BADS

In all conditions, changes in assessment of meaningful activities measured by the Behavioral Activation for Depression Scale (BADS). Scores are divided across 4 domains: Activation subscale scores range from 0-42, Avoidance/Rumination subscale scores range from 0-48, Work/School Impairment subscale scores range from 0-30, Social Impairment subscale scores range from 0-30. For all subscales, high scores are consistent with the subscale title (e.g., high scores on Activation subscale = more activation).

Time frame: Baseline, 6 weeks

Population: 40 subjects were analyzed at baseline. Due to participant withdrawal and loss to follow-up, the total number of participants at Week 6 was 30.

ArmMeasureGroupValue (MEAN)Dispersion
Video PROTECTChange in Assessment of Exposure to Meaningful Activities, as Measured by the BADSBaseline- Domain 417.79 units on a scaleStandard Deviation 7.66
Video PROTECTChange in Assessment of Exposure to Meaningful Activities, as Measured by the BADSBaseline- Domain 119.89 units on a scaleStandard Deviation 8.29
Video PROTECTChange in Assessment of Exposure to Meaningful Activities, as Measured by the BADSBaseline- Domain 222.46 units on a scaleStandard Deviation 8.57
Video PROTECTChange in Assessment of Exposure to Meaningful Activities, as Measured by the BADSBaseline- Domain 316.00 units on a scaleStandard Deviation 7.14
Video PROTECTChange in Assessment of Exposure to Meaningful Activities, as Measured by the BADSWeek 6- Domain 122.79 units on a scaleStandard Deviation 10.02
Video PROTECTChange in Assessment of Exposure to Meaningful Activities, as Measured by the BADSWeek 6- Domain 226.70 units on a scaleStandard Deviation 10.02
Video PROTECTChange in Assessment of Exposure to Meaningful Activities, as Measured by the BADSWeek 6- Domain 317.45 units on a scaleStandard Deviation 7.7
Video PROTECTChange in Assessment of Exposure to Meaningful Activities, as Measured by the BADSWeek 6- Domain 420.69 units on a scaleStandard Deviation 6.59
95% CI: [17.24, 22.54]
95% CI: [19.72, 25.2]
95% CI: [13.72, 18.28]
95% CI: [15.34, 20.24]
95% CI: [19.05, 26.53]
95% CI: [22.96, 30.44]
95% CI: [14.57, 20.33]
95% CI: [18.23, 23.15]

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026